216 related articles for article (PubMed ID: 27092313)
1. Application of a Plug-and-Play Immunogenicity Assay in Cynomolgus Monkey Serum for ADCs at Early Stages of Drug Development.
Carrasco-Triguero M; Davis H; Zhu Y; Coleman D; Nazzal D; Vu P; Kaur S
J Immunol Res; 2016; 2016():2618575. PubMed ID: 27092313
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of a generic immunoassay with drug tolerance to detect immune complexes in serum samples from cynomolgus monkeys after administration of human antibodies.
Stubenrauch K; Wessels U; Essig U; Vogel R; Schleypen J
J Pharm Biomed Anal; 2010 Jun; 52(2):249-54. PubMed ID: 20083366
[TBL] [Abstract][Full Text] [Related]
3. Detection of drug specific circulating immune complexes from in vivo cynomolgus monkey serum samples.
Pierog P; Krishna M; Yamniuk A; Chauhan A; DeSilva B
J Immunol Methods; 2015 Jan; 416():124-36. PubMed ID: 25462536
[TBL] [Abstract][Full Text] [Related]
4. Epitope characterization of the ADA response directed against a targeted immunocytokine.
Stubenrauch K; Künzel C; Vogel R; Tuerck D; Schick E; Heinrich J
J Pharm Biomed Anal; 2015 Oct; 114():296-304. PubMed ID: 26093509
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity of antibody drug conjugates: bioanalytical methods and monitoring strategy for a novel therapeutic modality.
Hock MB; Thudium KE; Carrasco-Triguero M; Schwabe NF
AAPS J; 2015 Jan; 17(1):35-43. PubMed ID: 25380723
[TBL] [Abstract][Full Text] [Related]
6. Quantitative determination of humanized monoclonal antibody rhuMAb2H7 in cynomolgus monkey serum using a Generic Immunoglobulin Pharmacokinetic (GRIP) assay.
Yang J; Ng C; Lowman H; Chestnut R; Schofield C; Sandlund B; Ernst J; Bennett G; Quarmby V
J Immunol Methods; 2008 Jun; 335(1-2):8-20. PubMed ID: 18402977
[TBL] [Abstract][Full Text] [Related]
7. Considerations for the nonclinical safety evaluation of antibody drug conjugates for oncology.
Roberts SA; Andrews PA; Blanset D; Flagella KM; Gorovits B; Lynch CM; Martin PL; Kramer-Stickland K; Thibault S; Warner G
Regul Toxicol Pharmacol; 2013 Dec; 67(3):382-91. PubMed ID: 24012707
[TBL] [Abstract][Full Text] [Related]
8. A double antigen bridging immunogenicity ELISA for the detection of antibodies to polyethylene glycol polymers.
Liu Y; Reidler H; Pan J; Milunic D; Qin D; Chen D; Vallejo YR; Yin R
J Pharmacol Toxicol Methods; 2011; 64(3):238-45. PubMed ID: 21827863
[TBL] [Abstract][Full Text] [Related]
9. Strategy and validation of a nonclinical generic plug-and-play antidrug antibody method for human monoclonal antibody biotherapeutics.
Polsky R; Gunn G; Reese KJ; Hottenstein CS; Gehman A; Schwartz A; Root D; Concannon A
Bioanalysis; 2024 Mar; 16(5):277-287. PubMed ID: 38334073
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity of antibody-drug conjugates: observations across 8 molecules in 11 clinical trials.
Carrasco-Triguero M; Dere RC; Milojic-Blair M; Saad OM; Nazzal D; Hong K; Kaur S
Bioanalysis; 2019 Sep; 11(17):1555-1568. PubMed ID: 31208199
[No Abstract] [Full Text] [Related]
11. Comparison of the NIDS® rapid assay with ELISA methods in immunogenicity testing of two biotherapeutics.
Pan J; Small T; Qin D; Li S; Wang L; Chen D; Pauley C; Verch T; Kaplanski C; Bakhtiar R; Vallejo YR; Yin R
J Pharmacol Toxicol Methods; 2011; 63(2):150-9. PubMed ID: 20868758
[TBL] [Abstract][Full Text] [Related]
12. Detection of low-affinity anti-drug antibodies and improved drug tolerance in immunogenicity testing by Octet(®) biolayer interferometry.
Li J; Schantz A; Schwegler M; Shankar G
J Pharm Biomed Anal; 2011 Jan; 54(2):286-94. PubMed ID: 20869832
[TBL] [Abstract][Full Text] [Related]
13. Attribution of the discrepancy between ELISA and LC-MS/MS assay results of a PEGylated scaffold protein in post-dose monkey plasma samples due to the presence of anti-drug antibodies.
Wang SJ; Wu ST; Gokemeijer J; Fura A; Krishna M; Morin P; Chen G; Price K; Wang-Iverson D; Olah T; Weiner R; Tymiak A; Jemal M
Anal Bioanal Chem; 2012 Jan; 402(3):1229-39. PubMed ID: 22130720
[TBL] [Abstract][Full Text] [Related]
14. Recommendations for the characterization of immunogenicity response to multiple domain biotherapeutics.
Gorovits B; Wakshull E; Pillutla R; Xu Y; Manning MS; Goyal J
J Immunol Methods; 2014 Jun; 408():1-12. PubMed ID: 24861938
[TBL] [Abstract][Full Text] [Related]
15. Emerging Technologies and Generic Assays for the Detection of Anti-Drug Antibodies.
Partridge MA; Purushothama S; Elango C; Lu Y
J Immunol Res; 2016; 2016():6262383. PubMed ID: 27556048
[TBL] [Abstract][Full Text] [Related]
16. Solution ELISA as a platform of choice for development of robust, drug tolerant immunogenicity assays in support of drug development.
Mikulskis A; Yeung D; Subramanyam M; Amaravadi L
J Immunol Methods; 2011 Feb; 365(1-2):38-49. PubMed ID: 21130095
[TBL] [Abstract][Full Text] [Related]
17. An Introduction to the Regulatory and Nonclinical Aspects of the Nonclinical Development of Antibody Drug Conjugates.
Lansita JA; Burke JM; Apgar JF; Mounho-Zamora B
Pharm Res; 2015 Nov; 32(11):3584-92. PubMed ID: 26108879
[TBL] [Abstract][Full Text] [Related]
18. Generic anti-drug antibody assay with drug tolerance in serum samples from mice exposed to human antibodies.
Stubenrauch K; Mackeben K; Vogel R; Heinrich J
Anal Biochem; 2012 Nov; 430(2):193-9. PubMed ID: 22935295
[TBL] [Abstract][Full Text] [Related]
19. Overcoming soluble target interference in an anti-therapeutic antibody screening assay for an antibody-drug conjugate therapeutic.
Carrasco-Triguero M; Mahood C; Milojic-Blair M; Amaya C; Ruppel J; Hong K; Yi JH; Kaur S
Bioanalysis; 2012 Aug; 4(16):2013-26. PubMed ID: 22946917
[TBL] [Abstract][Full Text] [Related]
20. Mitigation of Pre-existing Antibodies to a Biotherapeutic in Non-clinical Species When Establishing Anti-drug Antibody Assay Cutpoint.
Kumar SC; DelCarpini JA; Qu Q; Kane M; Gorovits B
AAPS J; 2017 Jan; 19(1):313-319. PubMed ID: 27873117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
